UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041754
Receipt number R000047614
Scientific Title Predictors of abatacept efficacy in immunomics
Date of disclosure of the study information 2020/11/01
Last modified on 2022/09/13 14:51:36

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Predictors of abatacept efficacy in immunomics

Acronym

PREDICTABA study

Scientific Title

Predictors of abatacept efficacy in immunomics

Scientific Title:Acronym

PREDICTABA study

Region

Japan


Condition

Condition

rheumatoid arthritis

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

YES


Objectives

Narrative objectives1

To examine abatacept(ABA) is similarly efficacious in disease activity improvement for the study patients as shown in previous reports.

Basic objectives2

Others

Basic objectives -Others

To extract genomic, transcriptomic and immunophenotypic factors which reflect ABA's efficacy in disease activity improvement.
To classify, experimentally, the patients into sub-groups with the factors and investigate ABA efficacy in the sub-groups.
To identify characters of patients in sub-groups for which ABA is more efficacious, and clarify the predictive factors of ABA efficacy from the patient characters.

Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Achievement of remission (DAS28-ESR<2.6) or improvement of disease activity (delta-DAS28-ESR>1.2) at Month 6

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients with RA meeting the 2010 ACR/EULAR Classification Criteria for RA
Patients with an inadequate response to at least one csDMARD previously
Patients aged 20 years or older at the informed consent for study participation
Patients aged 65 years or older or those with a concurrent condition that can increase the risk of infection
Patients starting abatacept therapy at the discretion of their primary physician

Key exclusion criteria

Patients treated with more than 3 types of biologics previously
Patients with a history of hypersensitivity to any of the ingredients of the abatacept product
Patients with a concurrent condition secondary to malignancy
Patients with active infection
Patients who are pregnant or breastfeeding, or those wishing pregnancy, childbearing, or breastfeeding
Patients ineligible for study participation in the opinion of the investigator or subinvestigator

Target sample size

105


Research contact person

Name of lead principal investigator

1st name Keishi
Middle name
Last name Fujio

Organization

Graduate School of Medicine, The University of Tokyo

Division name

Department of Allergy and Rheumatology

Zip code

113-8655

Address

7-3-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-3815-5411

Email

kfujio-tky@umin.ac.jp


Public contact

Name of contact person

1st name Yasuo
Middle name
Last name Nagafuchi

Organization

Graduate School of Medicine, The University of Tokyo

Division name

Department of Allergy and Rheumatology and Functional Genomics and Immunological Diseases

Zip code

113-8655

Address

7-3-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-3815-5411

Homepage URL


Email

nagafuchi-tky@umin.ac.jp


Sponsor or person

Institute

The University of Tokyo

Institute

Department

Personal name



Funding Source

Organization

Bristol Myers Squibb

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)

ONO PHARMACEUTICAL CO., LTD.


IRB Contact (For public release)

Organization

Graduate School of Medicine and Faculty of Medicine, The University of Tokyo Human Genome, Gene Analysis Research Ethics Committee

Address

7-3-1 Hongo, Bunkyo-ku, Tokyo

Tel

03-5841-3600

Email

ethics@m.u-tokyo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 11 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

105

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2019 Year 01 Month 11 Day

Date of IRB

2019 Year 05 Month 21 Day

Anticipated trial start date

2019 Year 08 Month 19 Day

Last follow-up date

2022 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The purpose of the study is to identify predictors of the effectiveness of abatacept. Integrated analyses of the genetic background of individual patients as well as pre-treatment peripheral-blood transcriptomes and detailed immune cell profiles, as determined by mass cytometry, have the potential to stratify RA patients suitable for abatacept therapy.


Management information

Registered date

2020 Year 09 Month 11 Day

Last modified on

2022 Year 09 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047614


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name